OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Choudhury on the Importance of Volume Status in Metastatic Prostate Cancer

June 12th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the importance of volume status in prostate cancer.

Dr. Clarke on Combination Approaches Beyond Progression on Osimertinib in Lung Cancer

June 12th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses combination approaches beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Karmali on Ibrutinib Maintenance Following Induction in Untreated MCL

June 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the preliminary results of a study which examined ibrutinib (Imbruvica) maintenance following induction in treatment-naïve patients with mantle cell lymphoma (MCL).

Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRC

June 12th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

Dr. Bochner on Future Treatment Strategies in Early-Stage NMIBC

June 12th 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses future treatment strategies in early-stage non–muscle invasive bladder cancer.

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

June 12th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

Dr. Shadman on Next Steps for CAR T-Cell Therapy in DLBCL

June 11th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Dorff Discusses the Use of PARP Inhibitors in Prostate Cancer

June 11th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

Dr. Nallapareddy on Treatment Options for Left- and Right-Sided CRC

June 11th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist, Rocky Mountain Cancer Centers, discusses treatment options for left- and right-sided colorectal cancer.

Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal 101 Trial in RCC

June 11th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, discusses findings from the subgroup analysis of the phase III JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Dr. Cobleigh on the Focus of Future Research in HER2+ Breast Cancer

June 11th 2019

Melody A. Cobleigh, MD, a professor of medical oncology at Rush University Medical Center, discusses the focus of future research in HER2-positive breast cancer.

Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer

June 11th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer.

Dr. Kang on the Preclinical Activity of ABC294640 in Multiple Myeloma

June 8th 2019

Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.

Dr. Zhu on TMB in Lung Cancer

June 8th 2019

Viola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.

Dr. McGregor on Advances Made in the Adjuvant Setting of RCC

June 8th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Dr. Philip on the Impact of the PRODIGE 24/CCTG PA.6 Study in Pancreatic Cancer

June 7th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the impact of the PRODIGE 24/CCTG PA.6 study in pancreatic cancer.

Dr. El-Rayes Discusses Methods of Locoregional Therapy in mCRC

June 7th 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.

Dr. Sonpavde on the Potential for Neoadjuvant Immunotherapy in Bladder Cancer

June 7th 2019

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Dr. Ou on Investigational KRAS Inhibitors in Lung Cancer

June 7th 2019

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

Dr. Lee on the ARAMIS Trial in M0CRPC

June 7th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses results from the phase III ARAMIS trial in nonmetastatic castration-resistant prostate cancer (M0CRPC).